Polpharma is the largest Polish manufacturer of drug products and active pharmaceutical ingredients. We specialize in manufacturing cardiological, gastrological and neurological drugs, which are prescribed and administered in inpatient healthcare. We also manufacture a wide range of OTC drugs.
A milestone in the company’s history was its privatization in 2000, based solely in the Polish capital. Its privatization gave the green light for thorough changes, which turned Polpharma into a strong and modern company, and a leader on the Polish pharmaceutical market.
Polpharma, together with Medana Pharma, wherein Polpharma is a majority shareholder, is the Polish market leader by volume of drug packages sold. At the same time, the company is reinforcing its position throughout international markets.
It has its own representative offices in Russia, Lithuania, Ukraine, Kazakhstan, Belarus, Vietnam, Azerbaijan and Uzbekistan.
Polpharma combines tradition and experience with modern technologies and the highest manufacturing standards.
We constantly increase the effectiveness of |
 |
our operations and use the elaborated benefits for further intensive development. Development is reflected, among others, in the company’s investments. Since 2000, Polpharma has invested approximately 700 m PLN.
Polpharma's greatest asset is its experienced and highly skilled staff. Approximately 2,600 people work at the Pharmaceutical Works in Starogard Gdański, in the Trade Office in Warsaw its branches in foreign markets for the company’s success.
Polpharma’s manufacturing activity is carried out in Starogard Gdański, at GMP-compliant facilities. The company utilizes up-to-date technologies, which ensure the safety of products, employees, and the natural environment. Manufacturing processes comply with all the environmental protection requirements of the European Union.
Polpharma’s annual capacity is approximately 200 m drug packages. In one of the largest and most modern drug manufacturing plants in Europe, the company manufactures solid drug forms, such as tablets, film-coated tablets, effervescent tablets, sugar coated tablets and capsules.
The annual manufacturing capacity of solid forms is 6 billion units. A fully hermetic manufacturing process allows for protection from any possible contamination and protects employees from contact with chemicals. |
|
Polpharma also manufactures parenteral drugs, injectable preparations in polyethylene packagings and glass ampoules, single- and multi-dose eye drops, nasal drops, infusion fluids and fluids for external use.
In 2005, the company started manufacturing in the new ampoule filling facility, wich was constructed in compliance with the strictest cGMP standards for sterile manufacturing.
Besides for finished drug forms, Polpharma manufactures active pharmaceutical ingredients. The capacity of the company’s reactors is 320 000 liters.
API manufacturing facilities are regularly audited by the FDA. Installations for the manufacturing of APIs and finished forms have GMP certificates that are issued by the Main Pharmaceutical Inspectorate and PIC/S (Pharmaceutical Inspection Cooperation Scheme).
Polpharma also offers contract manufacturing services of both drug products and active pharmaceutical ingredients.
Business Parter Section
Welcome to the section for business partners. Here, you will find information concerning various cooperation opportunities, active pharmaceutical ingredients, and finished dosage forms manufactured by Polpharma and research conducted by the Company.
For More Information Click Here:
|
|
|
